ACCC association of cancer care centers
Join/Renew
Login
Join/Renew
Login
Education & Resources
ACCC eXchange LogInCorporate Member Sponsored ResourcesPresentations & AbstractsACCC Connect eLearning LogIn
Publications
Oncology IssuesPatient Assistance & Reimbursement GuideTrending Now in Cancer CareBusiness Case Studies for Hiring New Staff
Events
2026 ACCC Leadership SummitAnnual Meeting & Cancer Center Business SummitCapitol Hill DayNational Oncology ConferenceOncology Reimbursement MeetingsOncology State Society Meetings
Policy & Advocacy
ACCC 2026 Policy PrioritiesLetters & StatementsAccess, Payment & Reimbursement ReformWhite Bagging & Brown BaggingAdvocacy ResourcesCancer Moonshot
Membership
Join | RenewWho We AreMembership Types & BenefitsCorporate MembersACCC Member Portal FAQMember Directory
Partners
Oncology State SocietiesPartner OrganizationsCME
News
News ReleasesAdvocacy News ReleasesOncology News
About ACCC
Timeline / 50th Anniversary2025 Impact ReportPresident's ThemeACCC Innovator AwardsACCC FellowsBoard of TrusteesACCC Senior Staff
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
Join/Renew
Login
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
    • Education & Resources
    • Publications
    • Events
    • Policy & Advocacy
    • Membership
    • Partners
    • News
    • About ACCC
ACCC association of cancer care centers
1801 Research Boulevard, Suite 400, Rockville, MD 20850
Tel: 301.984.9496 Email Us
Contact UsVolunteers
Advertise
Career Center
Terms and Conditions
Privacy Policy
ACCC Rebranding
Copyright © 2026 Association of Cancer Care Centers. All Rights Reserved.
HomeCANCER BUZZ Podcast

CMS’s Proposed Payment Rules for 2021: What You Need to Know

August 12, 2020

By Christian G. Downs, JD, MHA

On August 4, the Centers for Medicare & Medicaid Services (CMS) released its 2021 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules. The agency also released an accompanying executive order proposing increased flexibility for telehealth and rural healthcare in light of the COVID-19 pandemic.

CMS is waiving the 60-day publication requirement for the final rule and replacing it with a 30-day notification. The final rule will become effective January 1, 2021, although it may not be published until December 1, 2020. Comments on the proposed rule are due October 5, 2020.

OPPS Highlights

The OPPS proposed rule would continue many of the controversial policies CMS has implemented in recent years that have been upheld by the courts. These include the payment reduction for clinic visits at excepted (grandfathered) off-campus departments and the reduction in payment for drugs purchased under the 340B program. Overall, hospitals would see a 2.6% increase in payments under the proposed OPPS rule. This update is based on the projected hospital market basket increase of 3.0% minus a 0.4% adjustment for multi-factor productivity.

340B Program

CMS proposes increasing the 340B payment cut to ASP-28.7% from ASP-22.5%. The agency arrived at this number after concluding that survey data found an average acquisition cost of ASP-34.7%. CMS proposes to use ASP-34.7% as acquisition cost and add 6% of ASP for overhead and handling costs. CMS seeks comments on whether it should continue to pay for these drugs at ASP-22.5%. This policy has been the subject of ongoing litigation, and it was most recently upheld by the D.C. Circuit Court in July 2020.

CMS proposes continuing to reimburse drugs not purchased under the 340B program at ASP+6% if they have pass-through status or qualify for separate payment. The packaging threshold would remain at $130 for drugs without pass-through status.

Scope of Practice

CMS proposes to make permanent a policy finalized under the May 1 COVID-19 interim final rule that allows nurse practitioners, clinical nurse specialists, physician assistants, and certified nurse-midwives to supervise the performance of non-surgical extended duration therapy services (e.g., lengthy drug administration). Under current rules, these services require direct supervision (supervising practitioner is in the building and immediately available to assist) during the initiation of the service and general supervision for the rest of the service.

MAAAs

CMS proposes excluding certain cancer-related, protein-based multianalyte assays with algorithmic analyses (MAAAs) from the OPPS packaging policy and the date of service rule (14-day rule). This would allow these tests to be separately reimbursed under the Clinical Laboratory Fee Schedule.

PFS Highlights

Since the COVID-19 public health emergency (PHE) was declared earlier this year, CMS has issued waivers to increase flexibility and reduce regulatory burdens. In the PFS proposed rule, CMS proposes to make permanent, extend, or transition out of these new rules. ASCO notes that CMS estimates a plus-14% overall impact for hematology/oncology and a negative-6% impact for radiation oncology in 2021. The proposed CY 2021 PFS conversion factor is $32.26, a decrease of $3.83 from the CY 2020 MPFS conversion factor of $36.09.

E&M Visits

Per the CY 2020 MPFS final rule, beginning in 2021, CMS will largely align its E&M visit coding and documentation policies with changes enacted by the CPT® Editorial Panel for office/outpatient E&M visits. CMS proposes to clarify the times for which prolonged office/outpatient E&M visits can be reported and proposes revising the times used for rate-setting for this code set.

Quality Payment Program

Due to the COVID-19 pandemic, CMS will not introduce any Merit-based Incentive Payment System (MIPS) Value Pathways (MVP) for the 2021 performance period. CMS proposes a new alternative payment model (APM) performance pathway reporting option in 2021 to align with the MVP framework.

As part of the introduction of the performance pathway, CMS will sunset the CMS Web Interface as a collection type beginning in the 2021 performance period. CMS will continue to allow clinicians eligible for MIPS to participate in the program either as individuals or as part of a group or virtual group.

CMS is expanding the use of the APM entity submitter types to allow the use of all MIPS submission mechanisms. CMS proposes using performance period (rather than historical) benchmarks to score quality measures in 2021. The agency is concerned that it may not have a representative sample of historic data for 2019 (due to the pandemic), which would impact 2020 data submission, skewing benchmarking results.

Telehealth/Virtual Care

CMS proposes: 1) adding services to the Medicare telehealth list on a Category 1 basis, and 2) creating a third temporary category of criteria for services added to the Medicare telehealth list. “Category 3” will describe services added to the Medicare telehealth list during the COVID-19 PHE that will remain on the list through the calendar year in which the PHE ends.

In March 2020, CMS established separate payments for audio-only telephone E&M services. Although the agency is proposing to not continue to recognize these codes after the PHE ends, the agency states that it recognizes that “the need for audio-only interactions could remain as beneficiaries continue to try to avoid sources of potential infection, such as a doctor’s office.” Therefore, the agency is seeking comment on whether it should develop coding and payment for a service like the virtual check-in but for a longer unit of time and subsequently with a higher value. CMS is seeking comment on whether this service should be made permanent.

For the duration of the COVID-19 PHE, CMS has adopted an interim final policy revising the definition of direct supervision to include the virtual presence of the supervising practitioner using interactive audio/video real-time communications technology. CMS proposes continuing this policy through December 31, 2021.

Additional Resources

ACCC is reviewing these proposed rules and will provide comments by the Oct. 5 due date. To obtain further guidance from health policy experts about how these proposed rules may affect oncology practices, join our August 28 webcast at 3:00 pm EDT: CMS Proposed CY 2021 Payment Rules: What You Need to Know.

Christian G. Downs, JD, MHA, is executive director, Association of Cancer Care Centers.


The below is excerpted from the CMS fact sheet, Proposed Policy, Payment, and Quality Provisions Changes to the Medicare Physician Fee Schedule for Calendar Year 2021.

For CY 2021, CMS is proposing to add the following list of services to the Medicare telehealth list on a Category 1 basis. Services added to the Medicare telehealth list on a Category 1 basis are similar to services already on the telehealth list.



Additionally, we are proposing to create a third temporary category of criteria for adding services to the list of Medicare telehealth services. Category 3 describes services added to the Medicare telehealth list during the public health emergency (PHE) for the COVID-19 pandemic that will remain on the list through the calendar year in which the PHE ends.

CMS 2021 Proposed Rules Table 1

We are proposing to add the following list of services to the Medicare telehealth list on a Category 3 basis:



CMS 2020 Proposed Rules Table 2

Related Content

Innovation in Action: Breaking Down the 2025 ACCC Impact Report – [Mini Podcast] Ep. 228

April 10, 2026

Transforming Palliative Care in Oncology – [Video Podcast] Ep. 227

March 18, 2026

Streamlining Access to TIL Cell Therapy for Melanoma – [Podcast] Ep. 226

March 5, 2026

Policy in Practice: Change Hits the Clinic – [Podcast] Ep. 225

February 19, 2026

Addressing Psychosocial Distress With Psychedelic-Inspired Therapies – [Podcast] Ep. 224

February 9, 2026

Set Goals in Today’s Health Care Reality - [Podcast] Ep. 223

January 30, 2026

Plans for 2026: A Dialogue With ACCC’s Executive Director – [Video Podcast] Ep. 222

January 30, 2026

APPs Paving the Way in Leadership – [Podcast] Ep. 221

January 21, 2026

Upcoming Events

ACCC Oncology Reimbursement Meeting | Charleston
Oncology

ACCC Oncology Reimbursement Meeting | Charleston

In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
Register Now!
ACCC Oncology Reimbursement Meeting | St. Louis
Oncology

ACCC Oncology Reimbursement Meeting | St. Louis

In Person Meeting & NetworkingMay 13, 2026 at 8:00 AM CDT1335 South Lindbergh Boulevard, St. Louis, MO, USAHilton St. Louis Frontenac, St. Louis
Register Now!
ACCC 43rd National Oncology Conference
Oncology

ACCC 43rd National Oncology Conference

In Person Conference & ConventionOctober 21, 2026 at 8:00 AM MDT450 Summer St, Boston, MA 02210Omni Boston Hotel at the Seaport, Boston
Register Now!
Precision in Practice: Translating MRD Into Oncology Care
Oncology

Precision in Practice: Translating MRD Into Oncology Care

In Person Conference & ConventionApril 28, 2026 at 5:30 PM EDT1020 South Calhoun Street, Fort Wayne, IN, USAHilton Fort Wayne at the Grand Wayne Center, Fort Wayne
Register Now!
MOS 2026 Spring Conference
Oncology

MOS 2026 Spring Conference

In Person Conference & ConventionApril 28, 2026 at 5:15 PM CDT1111 East Broadway, Columbia, MO, USAThe Broadway Columbia (A DoubleTree by Hilton), Columbia
Register Now!
RIOS 2026 Spring Symposium
Oncology

RIOS 2026 Spring Symposium

In Person Conference & ConventionMay 9, 2026 at 11:00 AM EDT4 Richmond Square, Providence, RI 02906, USAWaterman Grille, Providence
Register Now!
 HSCO 2026 May Dinner Symposium
Oncology

HSCO 2026 May Dinner Symposium

In Person Conference & ConventionMay 13, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI, USARoy's Restaurants – Hawaii Kai, Honolulu
Register Now!
WSOS 2026 Laramie Meeting
Oncology

WSOS 2026 Laramie Meeting

In Person Conference & ConventionMay 20, 2026 at 5:30 PM MDT222 South 22nd Street, Laramie, WY, USAUniversity of Wyoming – Rochelle Gateway Center, Laramie
Register Now!
WAHO 2026 Welcome Reception
Oncology

WAHO 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 W Addison St, Chicago, IL, USAWrigley Field , Chicago
Register Now!
IOS 2026 Welcome Reception
Oncology

IOS 2026 Welcome Reception

In Person Conference & ConventionMay 30, 2026 at 6:00 PM CDT1060 West Addison Street, Chicago, IL, USAWrigley Field, Chicago
Register Now!
Advertisement
Advertisement

Trending Now on
ACCCBuzz Blog

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

Partnering to Deliver Targeted Treatment: Fox Chase Cancer Center and Omniscope

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.

View All ACCCBuzz Blogs

Join the Conversation

ACCC eXchange Digital Banner
Login